|
Título:
|
Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours
|
|
Autor/a:
|
Vedder, M.M.; Márquez, M.; Bekker-Grob de, E.W.; Calle, M. Luz; Dyrskjot, L.; Kogevinas, Manolis; Segersten, U.; Malmström, P.U.; Algaba, F.; Beukers, W.; Orntoft, T.F.; Zwarthoff, E.; Real, Francisco X.; Malats i Riera, Núria; Steyerberg, E.W.
|
|
Otros autores:
|
Universitat de Vic. Escola Politècnica Superior; Universitat de Vic. Grup de Recerca en Bioinformàtica i Estadística Mèdica |
|
Notas:
|
Abstract
Objective: We aimed to determine the validity of two risk scores for patients with non-muscle invasive bladder cancer in
different European settings, in patients with primary tumours.
Methods: We included 1,892 patients with primary stage Ta or T1 non-muscle invasive bladder cancer who underwent a
transurethral resection in Spain (n = 973), the Netherlands (n = 639), or Denmark (n = 280). We evaluated recurrence-free
survival and progression-free survival according to the European Organisation for Research and Treatment of Cancer
(EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) risk scores for each patient and used the
concordance index (c-index) to indicate discriminative ability.
Results: The 3 cohorts were comparable according to age and sex, but patients from Denmark had a larger proportion of
patients with the high stage and grade at diagnosis (p,0.01). At least one recurrence occurred in 839 (44%) patients and
258 (14%) patients had a progression during a median follow-up of 74 months. Patients from Denmark had the highest 10-
year recurrence and progression rates (75% and 24%, respectively), whereas patients from Spain had the lowest rates (34%
and 10%, respectively). The EORTC and CUETO risk scores both predicted progression better than recurrence with c-indices
ranging from 0.72 to 0.82 while for recurrence, those ranged from 0.55 to 0.61.
Conclusion: The EORTC and CUETO risk scores can reasonably predict progression, while prediction of recurrence is more
difficult. New prognostic markers are needed to better predict recurrence of tumours in primary non-muscle invasive
bladder cancer patients.
This research received funding from the European Community's Seventh Framework program FP7/2007-2011 under grant agreement 201663 (Uromol project, http://www.uromol.eu/) |
|
Materia(s):
|
-Càncer |
|
Derechos:
|
Aquest document està subjecte a aquesta llicència Creative Commons
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
|
|
Tipo de documento:
|
Artículo
info:eu-repo/acceptedVersion |
|
Editor:
|
Plos One
|
|
Compartir:
|
|
